A first-in-human study of biodistribution, safety, and dosimetry of a single-dose injection of 124I-JS001 in primary and metastatic tumor lesions
Latest Information Update: 17 May 2021
At a glance
- Drugs Toripalimab (Primary)
- Indications Malignant melanoma; Urogenital cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- 17 May 2021 New trial record
- 01 May 2021 Results published in the Clinical Nuclear Medicine